Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRAMADOL HYDROCHLORIDE vs ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: June 2026 · OpiCalc Medical Review Team
Tramadol hydrochloride is a centrally acting opioid analgesic that binds to μ-opioid receptors and inhibits the reuptake of norepinephrine and serotonin, modulating pain transmission in the central nervous system.
Acetaminophen: inhibits cyclooxygenase (COX) activity, reducing prostaglandin synthesis; analgesic and antipyretic. Caffeine: adenosine receptor antagonist; enhances analgesic effect. Dihydrocodeine: mu-opioid receptor agonist; produces analgesia via central opioid receptors.
Management of moderate to moderately severe pain (FDA-approved),Off-label: neuropathic pain, restless legs syndrome, osteoarthritis pain, fibromyalgia
Management of mild to moderate pain where treatment with an opioid is appropriate and for which alternative treatments are inadequate,Off-label: acute pain, chronic pain
50-100 mg orally every 4-6 hours as needed for pain, not to exceed 400 mg/day (100 mg for immediate-release).
1-2 tablets (each containing acetaminophen 300 mg, caffeine 30 mg, dihydrocodeine bitartrate 20 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
5-6 hours (parent drug); 7-9 hours (M1 active metabolite). In renal impairment, half-life prolonged up to 11 hours (parent) and 17 hours (M1).
Acetaminophen: 2-3 hours (normal), prolonged in hepatic impairment. Caffeine: 3-6 hours (adults), prolonged in liver disease or with oral contraceptives. Dihydrocodeine: 3.5-6 hours (terminal). Clinical context: q6h dosing interval appropriate; accumulation risk in renal/hepatic impairment.
Extensively metabolized via O- and N-demethylation in the liver primarily by cytochrome P450 2D6 (CYP2D6) and CYP3A4, producing active metabolite O-desmethyltramadol (M1).
Acetaminophen: primarily hepatic via glucuronidation and sulfation; minor CYP2E1, CYP1A2, CYP3A4. Caffeine: hepatic via CYP1A2. Dihydrocodeine: O-demethylation to dihydromorphine via CYP2D6; also via CYP3A4.
Primarily renal (90% total clearance, 30% as unchanged drug, 60% as metabolites); fecal (~10%); biliary minor.
Acetaminophen: renal excretion of metabolites (glucuronide 60%, sulfate 30%, cysteine/mercapturate 8%), <5% unchanged. Caffeine: renal excretion of metabolites (1-methyluric acid, 1-methylxanthine, etc.), <2% unchanged. Dihydrocodeine: renal excretion of metabolites (dihydrocodeine-6-glucuronide, nordihydrocodeine, dihydromorphine), ~20% unchanged. Overall, predominantly renal (≥85%), minor biliary/fecal.
~20% bound to albumin. Low binding reduces drug interactions.
Acetaminophen: 10-25% (albumin). Caffeine: 25-36% (albumin). Dihydrocodeine: ~20-30% (albumin and α1-acid glycoprotein).
2-3 L/kg (306 L total). Indicates extensive tissue distribution, including CNS penetration.
Acetaminophen: 0.7-1.0 L/kg. Caffeine: 0.5-0.8 L/kg. Dihydrocodeine: 1.0-1.5 L/kg. Clinical meaning: moderate distribution, potential for central nervous system penetration.
Oral: 70-75% (first-pass metabolism); IM: 100%; rectal: ~78% relative to oral; IV: 100%.
Acetaminophen: oral 75-85%. Caffeine: oral ~100%. Dihydrocodeine: oral ~20-30% (first-pass metabolism; extended-release formulations have altered bioavailability).
For Cr Cl < 30 m L/min: increase dosing interval to 12 hours; maximum dose 200 mg/day. For Cr Cl < 10 m L/min: not recommended.
GFR 30-50 m L/min: administer every 6 hours; GFR 10-30 m L/min: administer every 8 hours; GFR <10 m L/min: administer every 12 hours; avoid in severe impairment due to dihydrocodeine accumulation.
Child-Pugh Class B: reduce dose by 50% and extend interval to 12 hours. Child-Pugh Class C: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% or extend interval to every 8 hours; Child-Pugh C: avoid use due to acetaminophen hepatotoxicity and dihydrocodeine accumulation.
1-2 mg/kg/dose every 4-6 hours, not to exceed 8 mg/kg/day or 400 mg/day (whichever less). Not recommended for children < 12 years for post-operative pain.
Not recommended for children under 12 years due to dihydrocodeine risks; for adolescents 12-18 years: 1 tablet orally every 4-6 hours as needed, maximum 4 tablets per day (weight-based dosing not established).
Elderly (>75 years): use lowest effective dose, maximum 300 mg/day; extend dosing interval to 6-8 hours due to decreased clearance.
Initiate with 1 tablet orally every 6 hours; caution due to increased sensitivity to opioids and hepatotoxicity from acetaminophen; maximum 4 tablets per day; monitor renal and hepatic function.
WARNING: RISK OF MEDICATION ERRORS; ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P450 2D6 INTERACTION; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; SEROTONIN SYNDROME; HEPATIC TOXICITY
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion of acetaminophen can cause fatal hepatotoxicity; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Risk of serotonin syndrome when used with serotonergic drugs; risk of seizures in patients with epilepsy or those taking medications that lower seizure threshold; anaphylactic reactions; opioid-induced hyperalgesia; adrenal insufficiency; complex regional pain syndrome; withdrawal symptoms upon discontinuation.
Addiction, abuse, and misuse; respiratory depression; acetaminophen hepatotoxicity; drug interaction with benzodiazepines and CNS depressants; neonatal opioid withdrawal syndrome; risk of serotonin syndrome; severe hypotension; adrenal insufficiency; use in patients with head injury or increased intracranial pressure; seizures; avoid in patients with severe hepatic impairment.
Hypersensitivity to tramadol; acute or severe bronchial asthma; significant respiratory depression; gastrointestinal obstruction (including paralytic ileus); concurrent use of MAOIs or within 14 days of MAOI discontinuation; ethanol intoxication; severe hepatic impairment; use in children <12 years for postoperative tonsillectomy/adenoidectomy; known CYP2D6 ultra-rapid metabolizers.
Hypersensitivity to any component; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; suspected surgical abdomen; concomitant use with MAOIs or within 14 days; severe hepatic impairment.
Avoid alcohol consumption; may enhance CNS depression and increase risk of hepatotoxicity. Grapefruit juice may inhibit CYP2D6 and alter tramadol metabolism; limit intake. High-fat meals may delay absorption of immediate-release formulations but not significantly affect overall exposure.
Avoid alcohol; may increase risk of hepatotoxicity and CNS depression. High-fat meals may delay absorption but do not significantly affect overall exposure. Caffeine-containing foods and beverages may increase stimulant effects.
Tramadol hydrochloride is FDA Pregnancy Category C. First trimester: Limited human data; animal studies show increased skeletal variations and delayed ossification at maternally toxic doses. Second and third trimesters: Risk of neonatal respiratory depression, serotonin syndrome, and withdrawal if used near term. Avoid prolonged use or high doses.
Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity. Caffeine: High doses (>200 mg/day) associated with increased miscarriage risk; limited data on malformations. Dihydrocodeine: Opioid; first trimester: increased risk of neural tube defects (OR 2.0-2.5); third trimester: risk of neonatal opioid withdrawal syndrome (NOWS). Overall, combination product should be used only if benefit outweighs risks.
Tramadol and its active metabolite O-desmethyltramadol (M1) are excreted into breast milk. Milk-to-plasma ratio is approximately 2.2 for tramadol and 2.9 for M1. Relative infant dose is estimated at 2.88% of maternal weight-adjusted dose. Although generally considered compatible, monitor infant for sedation, respiratory depression, and withdrawal symptoms. Use lowest effective dose for shortest duration.
Acetaminophen: Excreted in breast milk (M/P ratio ~0.9); safe at therapeutic doses. Caffeine: Excreted (M/P ~0.5-0.8); moderate intake (<300 mg/day) generally safe. Dihydrocodeine: Excreted in low levels; however, interindividual variability in metabolism (CYP2D6) may lead to higher morphine concentrations in some infants; risk of neonatal respiratory depression. M/P ratio not well established for dihydrocodeine. Use with caution, monitor infant for sedation and feeding difficulties.
Pregnancy increases tramadol clearance due to enhanced hepatic metabolism and glomerular filtration. Dose adjustments are not standardized; however, increased doses may be needed to maintain analgesic efficacy. Use lowest effective dose and avoid during third trimester to prevent neonatal withdrawal and respiratory depression. Consider alternative analgesics if prolonged use required.
No specific dose adjustments for pregnancy due to lack of pharmacokinetic studies for this combination. However, note: Increased clearance of acetaminophen in pregnancy may require higher doses for analgesia but remains within standard limits. Caffeine clearance decreases in third trimester; consider reducing intake to <200 mg/day. Dihydrocodeine: Increased volume of distribution and clearance in pregnancy; dose may need titration but no established guidelines. Use lowest effective dose for shortest duration.
Tramadol is a prodrug requiring CYP2D6 metabolism to its active M1 metabolite for opioid analgesia; efficacy varies with CYP2D6 phenotype. Avoid concurrent use with MAOIs due to serotonin syndrome risk; use cautiously with SSRIs/SNRIs as additive serotonergic effects may occur. Tramadol lowers seizure threshold; avoid in patients with epilepsy or those taking other seizure threshold-lowering drugs. Renal impairment (Cr Cl < 30 m L/min) requires extended dosing interval (q12h). Do not exceed 400 mg/day (300 mg in elderly >75 years). Onset of analgesia is ~1 hour; peak effect at 2-3 hours.
Dihydrocodeine is a prodrug requiring CYP2D6 metabolism to active metabolites; poor metabolizers may have reduced efficacy while ultrarapid metabolizers risk toxicity. Caffeine potentiates analgesia and may cause insomnia with evening use. Do not exceed 8 tablets per 24 hours due to acetaminophen hepatotoxicity risk. Use with caution in elderly and patients with renal impairment.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,May cause dizziness or drowsiness; avoid driving or operating machinery until you know how this medication affects you.,Risk of serotonin syndrome if combined with other serotonergic drugs (e.g., antidepressants, migraine medications); seek immediate medical attention if symptoms like agitation, hallucinations, rapid heart rate, or fever occur.,Do not crush, chew, or dissolve extended-release tablets; swallow whole.,Avoid alcohol and sedatives (e.g., benzodiazepines) as they increase risk of respiratory depression and oversedation.,Do not stop abruptly; withdrawal symptoms may occur. Taper under medical supervision.,Store at room temperature, away from moisture and heat, and out of reach of children.,Report any history of seizures, head injury, or substance abuse to your doctor.
Take with food if stomach upset occurs.,Avoid alcohol and products containing acetaminophen to prevent liver damage.,Do not exceed 8 tablets in 24 hours.,May cause drowsiness; avoid driving or operating machinery until you know how this medication affects you.,If you have a history of drug dependence, use with caution as dihydrocodeine can be habit-forming.
"Concomitant use of tramadol and secobarbital increases the risk of severe adverse effects, including profound sedation, respiratory depression, coma, and death. This is due to additive central nervous system depression from both drugs. Patients should be closely monitored for signs of respiratory depression and excessive sedation."
"Coadministration of tramadol, a weak mu-opioid receptor agonist and serotonin-norepinephrine reuptake inhibitor (SNRI), with pargyline, a nonselective monoamine oxidase inhibitor (MAOI), poses a significant risk of serotonin syndrome. This potentially life-threatening condition results from excessive serotonergic activity in the central nervous system, manifesting as altered mental status, autonomic instability, and neuromuscular hyperactivity. Additionally, tramadol's metabolism via CYP2D6 to its active metabolite M1, and use with an MAOI may lead to hypertensive crisis due to enhanced noradrenergic effects."
"Lisuride, a dopamine agonist, and tramadol, an opioid analgesic with serotonergic activity, synergistically increase the risk of serotonin syndrome, a potentially life-threatening condition characterized by altered mental status, autonomic instability, and neuromuscular hyperactivity. The combination may also potentiate CNS depression, leading to excessive sedation, respiratory depression, and impaired psychomotor function. Concurrent use should be avoided or undertaken with extreme caution due to the heightened risk of serious adverse outcomes."
"The combination of chlordiazepoxide, a benzodiazepine that enhances GABAergic inhibition, and dihydrocodeine, an opioid agonist primarily at mu-receptors, results in additive central nervous system (CNS) depression. This synergy increases the risk of profound sedation, respiratory depression, coma, and death, particularly in vulnerable populations such as the elderly or those with pre-existing respiratory compromise. Concurrent use also elevates the potential for hypotension and psychomotor impairment, leading to falls or accidents."
"Reserpine depletes catecholamines in the central nervous system and peripheral adrenergic neurons, leading to reduced sympathetic outflow. Dihydrocodeine, an opioid agonist, can cause further central nervous system depression and hypotension. When combined, there is an additive risk of excessive hypotension, bradycardia, and profound sedation, potentially leading to falls or respiratory depression."
"Dihydrocodeine, an opioid analgesic, undergoes O-demethylation primarily via CYP2D6 to form dihydromorphine, which contributes to its analgesic effects. Clemastine, a first-generation antihistamine, is metabolized mainly by CYP2D6 as well. When co-administered, clemastine competitively inhibits CYP2D6, reducing the clearance of dihydrocodeine and decreasing the formation of the active metabolite dihydromorphine. This can lead to diminished analgesic efficacy and potentially increased levels of parent dihydrocodeine, heightening the risk of opioid-related adverse effects such as respiratory depression, sedation, and constipation."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRAMADOL HYDROCHLORIDE vs ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE, answered by our medical review team.
TRAMADOL HYDROCHLORIDE is a Opioid Agonist that works by Tramadol hydrochloride is a centrally acting opioid analgesic that binds to μ-opioid receptors and inhibits the reuptake of norepinephrine and serotonin, modulating pain transmission in the central nervous system.. ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE is a Opioid Agonist that works by Acetaminophen: inhibits cyclooxygenase (COX) activity, reducing prostaglandin synthesis; analgesic and antipyretic. Caffeine: adenosine receptor antagonist; enhances analgesic effect. Dihydrocodeine: mu-opioid receptor agonist; produces analgesia via central opioid receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRAMADOL HYDROCHLORIDE and ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE depend on the specific clinical indication. These are both Opioid Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRAMADOL HYDROCHLORIDE is: 50-100 mg orally every 4-6 hours as needed for pain, not to exceed 400 mg/day (100 mg for immediate-release).. The standard adult dose of ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE is: 1-2 tablets (each containing acetaminophen 300 mg, caffeine 30 mg, dihydrocodeine bitartrate 20 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRAMADOL HYDROCHLORIDE and ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRAMADOL HYDROCHLORIDE is classified as Category D/X. Tramadol hydrochloride is FDA Pregnancy Category C. First trimester: Limited human data; animal studies show increased skeletal variations and delayed ossification at maternally to. ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE is classified as Category D/X. Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity. Caffeine: High doses (>200 mg/day) associated with increased miscarriage risk; limited data . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.